PD-1/PD-L1抑制剂在妇科肿瘤的研究进展

Research Progress of PD-1/PD-L1 Inhibitors in the Treatment of Gynecological Cancers

目的:我国妇科恶性肿瘤的发病率长期居高不下,虽然早期患者可通过手术、放疗、化疗相结合的综合治疗方式获得较好的结局,但复发耐药患者的预后却不佳。近年来,肿瘤的免疫治疗发展迅速,其中针对程序性死亡受体-1(programmed cell death-1,PD-1)及其配体(programmed cell death ligand 1,PD-L1)的抗体已尝试用于治疗包括卵巢癌、宫颈癌、子宫内膜癌等多种妇科肿瘤。本文就PD-1/PD-L1免疫治疗在妇科肿瘤的研究进展作一综述。

The overall incidence of gynecological cancer is rising in china.Although patients in early stages have a relatively good prognosis,recurrence and drugs resistance,recurrent patients or drug-resistant patients are usually associated with a bad prognosis.Great progress has been made in cancer immunotherapy in recent years.New immunotherapies targeting programmed cell death 1(PD-1)/programmed cell death ligand 1(PD-L1)axis have been reported to give promising clinical responses in patients with gynecological cancers,including ovarian cancer,cervical cancer,endometrial cancer,etc.This article reviews the advances in research on PD-1/PD-L1 immunotherapy in gynecological cancer.